Microvascular Therapeutics receives $3.98M Award from CDMRPMVTOct 24, 20230 min readPR.com-Press-Release_MVT_DOD.pdfDownload PDF • 16KB
Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific SessionsSalt Lake City, UT – July 13, 2025 – Microvascular Therapeutics (MVT), a pioneering Utah based biotechnology company, is thrilled to...
Microvascular Therapeutics announces Founder and Chief Executive Officer (CEO) Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at 2025 BIO International ConventionBoston, MA – June 18, 2025 – Microvascular Therapeutics (MVT) is pleased to announce Founder and CEO, Dr. Evan Unger, as speaker on the...
Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)May 14th, 2025 Salt Lake City, Utah: Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed...
Commentaires